Loading...
XTAI
4746
Market cap184mUSD
Oct 08, Last price  
48.95TWD
1D
1.87%
1Q
-10.68%
Jan 2017
-50.81%
IPO
-47.34%
Name

Formosa Laboratories Inc

Chart & performance

D1W1MN
XTAI:4746 chart
P/E
13.34
P/S
1.21
EPS
3.67
Div yield, %
6.13%
Shrs. gr., 5y
-1.80%
Rev. gr., 5y
9.54%
Revenues
4.85b
+2.54%
02,505,914,0002,625,647,0002,524,282,0002,473,633,0002,496,224,0002,596,722,0003,189,380,0002,539,353,0002,687,731,0002,759,591,0003,075,457,0003,142,406,0003,765,504,0004,360,448,0004,731,046,0004,851,357,000
Net income
441m
+180.48%
0246,621,000231,067,0005,003,000-69,401,000262,495,000282,392,000483,441,000238,645,000176,821,000-41,062,000400,034,0001,249,096,000216,810,000126,243,000157,268,000441,107,000
CFO
1.32b
+81.08%
099,671,000-11,231,000171,135,00032,253,000280,408,000255,149,0001,110,075,000395,419,000-80,894,000289,924,000475,004,000311,157,000643,086,000826,600,000726,334,0001,315,247,000
Dividend
Aug 24, 20263 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services. In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support. Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.

Key people

Chairman of the Board, General Manager · since 2013
Hank Chen
Deputy General Manager-Production and Environment & Health & Safety Division · since 1997
Hengui Huang
Deputy General Manager-Quality Assurance Division · since 2014
Kevin Lee
Deputy General Manager-Research & Development Division · since 2019
Josh Lin
Deputy General Manager-Engineering Division · since 2009
Chien Hsing Lin
Deputy General Manager-Legal & Strategy Planning Division · since 2020
Jessica Liou
Deputy General Manager-Marketing & Sales Division · since 1996
Michelle Lo
Deputy General Manager-Finance Division, Head of Corporate Governance · since 2022
Jeff Sung
Deputy General Manager-Injectable Division · since 2018
J.C. Wung
Deputy General Manager-Quality Control Division · since 2021
Fannie Yang
Deputy General Manager-Operational Support Division · since 2020
Qianfei Lin
Chief Information Security Officer · since 2023
Pei Fang
Director · since 2023
Yi Kan Hu
Director · since 2022
Jianhong Li
Director · since 2014
Director · since 2016
Lujie Wang
Director · since 2008
Hongmin Xie
Director · since 2006
Zhihan Zhong
Director · since 2008
Yi Fen Chen
Independent Director
IPO date
Nov 27, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT